RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $98 from $95 and keeps an Outperform rating on the shares. The ...
On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the ...
Neurology Sales Growth: 10% in Q3 2024. Endoscopy Sales Growth: 7% organically in Q3 2024. Boston Scientific Corp ...
Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the shares. The ...
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback